Status:
COMPLETED
Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore
Lead Sponsor:
King Edward Medical University
Conditions:
COVID-19
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine, ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled trials (RCTs) for efficacy and/...
Detailed Description
Coronavirus diseases 2019 (COVID-19) is caused by a novel β-coronavirus which is named as SARS-CoV-2. SARS-CoV-2 shares 79% RNA sequence identity with severe acute respiratory syndrome coronavirus 2 (...
Eligibility Criteria
Inclusion
- All Patients with confirmed COVID-19 of either gender and aged 12 years and above.
- Patients having Severe COVID 19 Disease. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤94% on room air or requiring supplemental oxygen or requiring mechanical ventilation or requiring extracorporeal membrane oxygenation (ECMO).17
- \-
Exclusion
- Known severe allergic reaction to Remdesivir or to other antiviral drugs
- Patients already having other treatments like tocilizumab or other antiviral drugs
- Pregnancy or breastfeeding
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>5 times upper normal limit
- Creatinine clearance \<30ml/min
- Low platelet count \<50,000/l
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04871633
Start Date
August 1 2020
End Date
December 30 2020
Last Update
May 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Hospital
Lahore, Punjab Province, Pakistan, 54000